A Conceptual Model of Financial Toxicity in Pediatric Oncology

Sheila Judge Santacroce1, Shawn M Kneipp1

  • 11 The University of North Carolina at Chapel Hill, NC, USA.

Insights

Financial toxicity, the impact of cancer treatment costs on families, is a critical issue in pediatric oncology. This framework guides nurses to address financial distress and improve child health outcomes.

Area of Science:

  • Oncology Nursing
  • Health Economics
  • Pediatric Health

Background:

  • Financial toxicity is a significant burden for families of children with cancer.
  • Existing frameworks for financial toxicity in adults require adaptation for the pediatric context.
  • A systematic scoping review identified gaps in understanding parental financial burden in pediatric oncology.

Purpose of the Study:

  • To explicate a conceptual framework for financial toxicity in pediatric oncology.
  • To guide nursing practice and research in addressing financial toxicity.
  • To adapt existing financial outcomes models for the pediatric cancer population.

Main Methods:

  • Adaptation of a conceptual framework for financial outcomes of severe illness.
  • Informed by a systematic scoping review of literature on parental costs in pediatric oncology.
  • Development of a conceptual model specific to pediatric oncology.

Main Results:

  • The pediatric oncology framework highlights the influence of parent/family factors, risk factors, and treatment costs on financial coping and outcomes.
  • Parental financial distress and outcomes can impact child health outcomes.
  • Financial toxicity is a relevant nursing role, aligning with holistic care principles.

Conclusions:

  • Pediatric oncology nurses should be aware of financial toxicity and its risk factors.
  • Nurses need to communicate effectively about treatment costs and financial distress.
  • Collaboration among stakeholders is essential to mitigate financial toxicity's impact on childhood cancer outcomes.

Related Concept Videos

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
208
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
225
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.9K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
285
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
213
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
272